HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Honest Company Now Defending 'Natural' Claims On Both Coasts

This article was originally published in The Rose Sheet

Executive Summary

Already embroiled in litigation in California, Honest now faces a proposed class action in New York citing a laundry list of chemicals and at least 40 of its personal-care and household products as evidence of false "natural" advertising and other violations. The legal woes could complicate a valuation of the company as it reportedly is exploring an initial public offering.

You may also be interested in...

Global Beauty And Personal Care Growth Unleashed Despite Market Tensions In Changed World

The Global Wellness Institute outlines trends shaping the post-pandemic beauty and personal-care space, projected to see annual growth in excess of 8% from 2020 through 2025.

2016 In Review: ‘Free Of’ Claims, Ingredient Snafus Breed Controversy

Undeclared ingredient use by Ava Anderson Non Toxic and the presence of sodium lauryl sulfate in Honest Company products, contrary to its “free of” claims, led to the former’s collapse and class action litigation against the latter in 2016. Meanwhile, “natural” marketing continues to be a risky business, with FTC stepping up enforcement action last year and efforts underway to promote clearer legal standards.

MGC Derma Ups Ante In 'Green' Skin Care With Cannabis-Based Debut

The 14-product Ananda CBD Cosmetics line features a non-psychoactive cannabis extract with powerful antioxidant, anti-aging, anti-inflammatory and analgesic properties, according to the personal-care division of Australia-based MGC Pharmaceuticals. Meanwhile, the company is in clinical trials with an eye toward marketing OTC drugs that treat acne, psoriasis and seborrheic dermatitis.

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts